Pfizer-BioNTech vaccine shot could help end the COVID-19 pandemic – Israeli Study
|Pfizer/ BioNTech’s jointly developed COVID-19 vaccine emerges extremely effective against the virus in a study that was conducted among 1.2 million Israeli people, Bloomberg reports, citing a study conducted by the teams from the Clalit Research Institute and Harvard University.
Additional details
“Two doses of the vaccine prevented 94% of Covid-19 cases in 596,618 people vaccinated between Dec. 20 and Feb. 1, about one-quarter of whom were over the age of 60.”
“After two doses, the vaccine was just as effective for adults age 70 and older as it was for younger people. There were indications that the shot might work slightly less well for people who were sick with three or more other illnesses, such as high blood pressure and diabetes.”
“But the benefit remained strong, with 89% protection from Covid symptoms seven days after the second dose. And for most people, protection was already significant two to three weeks after the first dose.”
Market reaction
The encouraging vaccine news could likely add to the reflation trade-optimism, as the S&P 500 futures rise 0.19% to 3,930 levels.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.